A study conducted by Tada et al. [46] ascertained an independent association between a high pre-treatment serum CRP/ALB ratio and worse OS in HCC patients receiving molecular targeted therapy with lenvatinib. The gene discussed is ALB; the disease is hepatocellular carcinoma.